SHPH 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
SHPH 近期報酬表現
-2.84%
Shuttle pharmaceuticals holdings inc
4.57%
同產業平均
0.12%
S&P500
與 SHPH 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
PYPD | Polypid ltd | 1 分 | 1 分 | 2 分 | 1 分 | 1 分 | |
LBPH | Longboard pharmaceuticals inc | 2 分 | 4 分 | 3 分 | 2 分 | 1 分 | |
INCY | Incyte corp | 4 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
MNMD | Mind medicine (mindmed) inc | 1 分 | 3 分 | 3 分 | 1 分 | 1 分 | |
ELUT | Elutia inc | 2 分 | 4 分 | 2 分 | 1 分 | 1 分 |
- PYPD Polypid ltd價值 1 分趨勢 1 分波段 2 分籌碼 1 分股利 1 分查看更多
SHPH 公司資訊
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.